CERALAS G ND;YAG LASER SYSTEM (CERALAS G)

K962948 · Ceram Optec, Inc. · GEX · Oct 25, 1996 · General, Plastic Surgery

Device Facts

Record IDK962948
Device NameCERALAS G ND;YAG LASER SYSTEM (CERALAS G)
ApplicantCeram Optec, Inc.
Product CodeGEX · General, Plastic Surgery
Decision DateOct 25, 1996
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 878.4810
Device ClassClass 2
AttributesTherapeutic

Intended Use

The Ceralas G is intended to be used as a surgical instrument for photocoagulation of ocular tissue as well as ablation of tissue of the iris and trabeculum. It is already cleared for photocoagulation of retinal tissue.

Device Story

Ceralas G is a compact, self-contained Nd:YAG surgical laser system. Device utilizes fiber optic delivery system; connects to standard slit lamps (Carl Zeiss, Haag-Streit) or Keeler indirect ophthalmoscopes via company-provided adaptors. Operated by physicians in clinical settings. Laser emits 532 nm wavelength treatment beam; operates in continuous or pulsed modes (0.1–1 sec duration). Physician controls power output (0.1–3 W) via user interface; manual instructs starting at low power/duration, titrating upward to achieve desired tissue effect. Device enables photocoagulation of ocular/retinal tissue and ablation of iris/trabecular tissue. Benefits include precise tissue interaction for ophthalmic procedures.

Clinical Evidence

No clinical data provided. Substantial equivalence is based on technological characteristics, intended use, and comparison of performance specifications (wavelength, power, exposure duration) against predicate devices.

Technological Characteristics

Compact Nd:YAG surgical laser; 532 nm wavelength; 0.1–3 W power output; 0.1–1 sec pulsed exposure duration. Compatible with slit lamps and indirect ophthalmoscopes via fiber optic delivery. Includes minor software modifications for delivery system integration. Self-contained system.

Indications for Use

Indicated for photocoagulation of ocular/retinal tissue and ablation of iris and trabecular tissue in patients requiring ophthalmic laser surgery.

Regulatory Classification

Identification

(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.

Predicate Devices

Reference Devices

Related Devices

Submission Summary (Full Text)

{0} OCT 25 1996 k962948 510(k) Summary For CeramOptec, Inc.'s Ceralas G Frequency Doubled Nd:YAG Laser Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared: Jonathan S. Kahan, Esq. Hogan & Hartson L.L.P. 555 13th Street N.W. Washington, D.C. 20004-1109 Phone: (202) 637-5794 Facsimile: (202) 637-5910 as Regulatory Counsel to CeramOptec, Inc. Contact Person: Same as above Date Prepared: July 14, 1996 Name of Device and Name/Address of Sponsor: Ceralas G Frequency Doubled Nd:YAG Laser System and accessories CeramOptec, Inc. 515 Shaker Road East Longmeadow, MA 01028 Classification Name: Ophthalmic laser Predicate Devices: 1. Biovision Crystal Emerald Focus 2. Zeiss Diode Pumped Solid State Laser 3. Coherent Innova Argon and Coherent Series 599 Dye Laser 4. HGM Compac 110 Argon Laser \DOC - 61213/1 - 0305121.01 {1} # Intended Use The Ceralas G is intended to be used as a surgical instrument for photocoagulation of ocular tissue as well as ablation of tissue of the iris and trabeculum. It is already cleared for photocoagulation of retinal tissue. # Technical Characteristics and Substantial Equivalence The Ceralas G is a complete self-contained compact surgical laser that utilizes a neodymium-doped yttrium aluminum garnet ("Nd:YAG") crystal. The Ceralas G has already been cleared by FDA (K954834) for use as a surgical instrument for photocoagulation of retinal tissue using a hand held fiber optic delivery system. The purpose of this submission is to extend the indications for use of the cleared laser to include photocoagulation of ocular tissue and ablation of tissue of the iris and trabeculum. As explained in this 510(k) notice, the Ceralas G can be attached using an adaptor provided by the Company, without hardware modification, to the Carl Zeiss (K874160 and K925641) or Haag-Streit (K792083) slit lamps, and to the Keeler indirect ophthalmoscopes (K854244 and K942104). No hardware changes have been made to the originally cleared Ceralas G laser. Only certain minor software modifications are required to use the slit lamp as a delivery system. Use of the Ceralas G laser with slit lamps and indirect ophthalmoscopes permits photocoagulation of ocular tissue and ablation of tissue of the iris and trabeculum with the Ceralas G laser. The CeramOptec fiber optic laser delivery system intended for use with the Ceralas G Nd:YAG Laser System has already received clearance from FDA (K935747). The Ceralas G and the predicates have the same indications for use; photocoagulation of ocular tissue (Biovision Laser, Zeiss Laser, and Coherent Laser) as well as ablation of tissue of the iris and trabeculum (HGM Laser). The lasers are all intended to be used with slit lamps, indirect ophthalmoscopes, and endocular probes. The Ceralas G was cleared for photocoagulation of retinal tissue. This submission expands the intended use of the Ceralas G to use with slit lamps and indirect ophthalmoscopes. The lasers also have very similar treatment beam wavelengths and powers, and can operate in both continuous and pulsed exposure modes. The wavelength of the treatment beam for the Ceralas G, the Biovision Laser, and the Zeiss Laser is 532 nm, and the wavelength of the Coherent Laser is in a range consisting of 488 - 514 nm and 577 - 630 nm. They also have very similar treatment beam power outputs. The Ceralas G and the Biovision Laser both can provide a treatment beam of 0.1 - 3 Watts ("W"). The Zeiss Laser can provide a treatment beam of 0.1 - 1 W and the Coherent Laser can provide a treatment beam of 0.1 - 4 W (Argon) and 0.05 W - 170 W (Dye). The Ceralas G has a pulsed mode exposure duration of 0.1 - 1 sec; the Biovision Laser, 0.01 - 3 sec; the Zeiss Laser, 0.01 - 0.5 sec; and the Coherent Laser, 0.01 - 5 sec. The differences in pulsed mode \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ Page 2 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ {2} exposure duration between the Ceralas G and the predicates do not raise new issues of safety or effectiveness because the range of exposure durations is very similar between the Ceralas G and the predicate lasers. The Ceralas G and the HGM Laser both have very similar treatment beam wavelengths and powers, and can operate in both continuous and pulsed exposure modes. The wavelength of the Ceralas G's treatment beam is at 532 nm and the HGM Laser's treatment beam is distributed in a range between 488 - 529 nm with the largest line at 514 nm. The difference in wavelength between the Ceralas G and the HGM Laser does not raise any new issues of safety or effectiveness because the wavelength range for the HGM Laser includes a wavelength within 3 nm of the wavelength emitted by the Ceralas G. Both lasers also have very similar treatment beam power outputs. The Ceralas G's treatment beam power output is 0.1 - 3 W and the HGM Laser's treatment beam power output is 0.1 - 1 W. The Ceralas G has a pulsed mode exposure duration of 0.1 - 1 sec and the HGM Laser has a pulsed mode exposure duration of 0.01 - 0.5 sec. Although the Ceralas G can achieve power outputs up to 3 W and use a 1 sec exposure duration, the User's Manual instructs the physician to start a procedure using only 0.1 W of power and an exposure duration of 0.1 - 0.2 seconds. The physician is instructed to then gradually increase the power or exposure duration to achieve the desired tissue effect. Thus, the difference in maximum power output and exposure duration does not raise new issues of safety or effectiveness because the physician is instructed to use a power only as high and an exposure duration only as long as necessary to achieve the desired tissue effect. The minor differences in the wavelength and power of the treatment beams do not raise any new issues of safety or effectiveness because: (1) the Ceralas G and the predicate lasers all can be operated with a slit lamp, an indirect ophthalmoscope and a fiber optic delivery system; (2) the Ceralas G and the Biovision Laser are indicated for photocoagulation of ocular tissue, have a very similar pulsed mode exposure duration, and have a treatment beam which operates at 532 nm with 0.1 - 3 W of power; (3) the Ceralas G and the HGM Laser, both of which are indicated for ablation of tissue of the iris and trabeculum, have very similar treatment beam wavelengths; and (4) while there are minor differences in the power and pulsed mode exposure duration of the treatment beam between the Ceralas G and the HGM Laser, the Ceralas G's User's Manual instructs the physician to start with a low power and exposure duration and increase to achieve the desired tissue effects. Any other minor differences between the Ceralas G and the predicate devices, such as the systems' dimensions and weight, do not raise new questions of safety and effectiveness. \DC-61213/1-0305121.01
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%